JP2021528449A5 - - Google Patents

Info

Publication number
JP2021528449A5
JP2021528449A5 JP2020571762A JP2020571762A JP2021528449A5 JP 2021528449 A5 JP2021528449 A5 JP 2021528449A5 JP 2020571762 A JP2020571762 A JP 2020571762A JP 2020571762 A JP2020571762 A JP 2020571762A JP 2021528449 A5 JP2021528449 A5 JP 2021528449A5
Authority
JP
Japan
Prior art keywords
compound according
spp
residue
compound
leucine
Prior art date
Application number
JP2020571762A
Other languages
English (en)
Japanese (ja)
Other versions
JP7488774B2 (ja
JPWO2020002325A5 (https=
JP2021528449A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2019/066819 external-priority patent/WO2020002325A1/en
Publication of JP2021528449A publication Critical patent/JP2021528449A/ja
Publication of JPWO2020002325A5 publication Critical patent/JPWO2020002325A5/ja
Publication of JP2021528449A5 publication Critical patent/JP2021528449A5/ja
Priority to JP2024077064A priority Critical patent/JP2024109664A/ja
Application granted granted Critical
Publication of JP7488774B2 publication Critical patent/JP7488774B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020571762A 2018-06-25 2019-06-25 化合物 Active JP7488774B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024077064A JP2024109664A (ja) 2018-06-25 2024-05-10 化合物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862689602P 2018-06-25 2018-06-25
US62/689,602 2018-06-25
PCT/EP2019/066819 WO2020002325A1 (en) 2018-06-25 2019-06-25 Compounds

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024077064A Division JP2024109664A (ja) 2018-06-25 2024-05-10 化合物

Publications (4)

Publication Number Publication Date
JP2021528449A JP2021528449A (ja) 2021-10-21
JPWO2020002325A5 JPWO2020002325A5 (https=) 2022-07-07
JP2021528449A5 true JP2021528449A5 (https=) 2022-07-07
JP7488774B2 JP7488774B2 (ja) 2024-05-22

Family

ID=67107423

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020571762A Active JP7488774B2 (ja) 2018-06-25 2019-06-25 化合物
JP2024077064A Pending JP2024109664A (ja) 2018-06-25 2024-05-10 化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024077064A Pending JP2024109664A (ja) 2018-06-25 2024-05-10 化合物

Country Status (31)

Country Link
US (3) US11459357B2 (https=)
EP (2) EP4316504A3 (https=)
JP (2) JP7488774B2 (https=)
KR (1) KR20210054500A (https=)
CN (2) CN112789287B (https=)
AR (1) AR116663A1 (https=)
AU (2) AU2019294261B2 (https=)
BR (1) BR112020026663A2 (https=)
CA (1) CA3103158A1 (https=)
CO (1) CO2020016080A2 (https=)
DK (1) DK3810633T3 (https=)
EA (1) EA202092819A1 (https=)
ES (1) ES2971732T3 (https=)
FI (1) FI3810633T3 (https=)
HR (1) HRP20240028T1 (https=)
HU (1) HUE065134T2 (https=)
IL (2) IL279620B2 (https=)
LT (1) LT3810633T (https=)
MA (1) MA52946B1 (https=)
MD (1) MD3810633T2 (https=)
MX (1) MX2020013811A (https=)
PH (1) PH12020552240A1 (https=)
PL (1) PL3810633T3 (https=)
PT (1) PT3810633T (https=)
RS (1) RS65128B1 (https=)
SG (1) SG11202012747VA (https=)
SI (1) SI3810633T1 (https=)
TW (2) TWI851584B (https=)
UA (1) UA128162C2 (https=)
WO (1) WO2020002325A1 (https=)
ZA (1) ZA202301937B (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12146004B2 (en) 2014-11-26 2024-11-19 Spero Therapeutics, Inc. Polymyxin compounds and uses thereof
RS65128B1 (sr) * 2018-06-25 2024-02-29 Spero Therapeutics Inc Jedinjenja
WO2022098950A1 (en) 2020-11-06 2022-05-12 Spero Therapeutics, Inc. Compounds
WO2022262823A1 (zh) * 2021-06-18 2022-12-22 华南理工大学 活性氧自由基响应的多粘菌素前药化合物及其应用
CN121426894A (zh) * 2025-07-24 2026-01-30 中国药科大学 一种抗菌肽、药物组合物及应用
CN120699105B (zh) * 2025-08-19 2025-11-21 中国药科大学 一种氘代抗菌肽及其组合物和应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2128617A (en) 1982-10-06 1984-05-02 Martti Vaara Polypeptides for use in antibacterial therapy
AU7753787A (en) 1986-08-06 1988-02-24 Jean-Luc Fauchere Production of covalent-linked conjugates from an antibiotic and a non-toxic derivative of polymyxine b
US20010021697A1 (en) 1987-09-14 2001-09-13 Henning Lowenstein Methods and compositions for the treatment of mammalian infections employing medicaments comprising hymenoptera venom, proteinageous or polypeptide components thereof, or analogues of such proteinaceous or polypeptide components
TW274552B (https=) 1992-05-26 1996-04-21 Hoechst Ag
US5767068A (en) 1997-02-13 1998-06-16 Pathogenesis Corporation Pure biologically active colistin, its components and a colistin formulation for treatment of pulmonary infections
CA2540742A1 (en) 2003-09-30 2005-04-14 Terry Hicks Compositions and methods for treating burns
US20060004185A1 (en) 2004-07-01 2006-01-05 Leese Richard A Peptide antibiotics and peptide intermediates for their prepartion
BRPI0715095B8 (pt) 2006-08-11 2021-05-25 Northern Antibiotics Oy derivado de polimixina da fórmula geral (i); produto de combinação; composição farmacêutica; método para se sensibilizar bactérias gram-negativas a um agente antibacteriano; método para o desenvolvimento de antibióticos; método para a redução da toxicidade de polimixinas, octapeptinas naturais e seus derivados durante a aplicação das mesmas no tratamento de infecções em um indivíduo; método para melhorar as propriedades farmacocinéticas, de polimixinas, octapeptinas naturais e seus derivados; método para a sensibilização de bactérias gram-negativas clinicamente importantes a um complemento de mecanismo de defesa presente no soro; uso de um derivado; e processo para a preparação de um derivado de polimixina da fórmula (i).
US7807637B2 (en) 2006-08-11 2010-10-05 Northern Antibiotics Oy Polymyxin derivatives and uses thereof
FI20085469A0 (fi) 2008-02-08 2008-05-16 Northern Antibiotics Oy Polymyksiinijohdannaiset, joissa on lyhyt rasvahappohäntä, ja niiden käyttöjä
US8193148B2 (en) 2008-02-08 2012-06-05 Northern Antibiotics Ltd. Short fatty acid tail polymyxin derivatives and uses thereof
US8329645B2 (en) 2008-02-08 2012-12-11 Northern Antibiotics Ltd. Polymyxin derivatives and uses thereof
ES2334547B1 (es) 2008-09-10 2010-12-03 Universidad De Barcelona Compuestos peptidicos antibacterianos.
CA2747995A1 (en) 2008-12-23 2010-07-01 Biosource Pharm, Inc. Antibiotic compositions for the treatment of gram negative infections
CN101851270A (zh) 2009-04-03 2010-10-06 梁浩 一种多粘菌素衍生物及其制备方法
WO2010130007A1 (en) 2009-05-14 2010-11-18 Monash University Antimicrobial compounds
US8415307B1 (en) 2010-06-23 2013-04-09 Biosource Pharm, Inc. Antibiotic compositions for the treatment of gram negative infections
WO2012051663A1 (en) 2010-10-21 2012-04-26 Monash University Antimicrobial compounds
WO2012168820A1 (en) * 2011-06-08 2012-12-13 Pfizer Inc. Polymyxin derivatives useful as antibacterial agents
CA2855916A1 (en) 2011-11-18 2013-05-23 Novacta Biosystems Limited Polymyxin derivatives
KR102354902B1 (ko) 2013-05-22 2022-01-24 에버레스트 메디신즈 (싱가포르) 피티이. 리미티드 폴리믹신 유도체 및 상이한 항생제와의 조합 요법에 있어서의 이들의 용도
MX359104B (es) 2014-03-11 2018-09-14 New Pharma Licence Holdings Ltd Derivados de polimixina y su uso en terapia de combinacion junto con diferentes antibioticos.
JP2017512818A (ja) 2014-04-01 2017-05-25 モナシュ、ユニバーシティMonash University 抗菌性化合物としてのポリミキシン誘導体
US12146004B2 (en) 2014-11-26 2024-11-19 Spero Therapeutics, Inc. Polymyxin compounds and uses thereof
SG11201704627XA (en) * 2014-12-17 2017-07-28 Hoffmann La Roche Enzymatic one-pot reaction for double polypeptide conjugation in a single step using sortase
WO2016166103A1 (en) * 2015-04-13 2016-10-20 Xellia Pharmaceuticals Aps Polymyxin derivatives
EP3356387B1 (en) * 2015-09-29 2024-06-26 Monash University Antimicrobial polymyxin derivative compounds
US10428122B2 (en) * 2016-06-16 2019-10-01 International Aids Vaccine Initiative, Inc. Tuberculosis compositions and methods of treating or preventing tuberculosis
RS65128B1 (sr) * 2018-06-25 2024-02-29 Spero Therapeutics Inc Jedinjenja
WO2020014501A1 (en) 2018-07-11 2020-01-16 Cidara Therapeutics, Inc. Compositions and methods for the treatment of bacterial infections

Similar Documents

Publication Publication Date Title
JP2021528449A5 (https=)
JP2017510570A5 (https=)
JP2014533678A5 (https=)
MY192109A (en) Aminopyrimidinyl compounds as jak inhibitors
HRP20240028T1 (hr) Spojevi
RU2014143821A (ru) 1, 3, 4-ОКСАДИАЗОЛЬНЫЕ И 1, 3, 4-ТИАДИАЗОЛЬНЫЕ ИНГИБИТОРЫ β-ЛАКТАМАЗЫ
HRP20221217T1 (hr) Spojevi inhibitori beta-laktamaze
JP2011513305A5 (https=)
JP2009544602A5 (https=)
JP2015535847A5 (https=)
JP2019516713A5 (https=)
WO2020047399A8 (en) Ionizable lipidoids and their uses
JP2021523241A5 (https=)
JP2015528468A5 (https=)
JP2016505007A5 (https=)
JP2016503778A5 (https=)
JP2019519512A5 (https=)
JP2017538692A5 (https=)
JP2018500387A5 (https=)
JP2016528257A5 (https=)
JPWO2020002325A5 (https=)
JP2019501123A5 (https=)
JP2019534893A5 (https=)
JP2019501896A5 (https=)
JP2018523675A5 (https=)